[go: up one dir, main page]

MX2015009429A - Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina. - Google Patents

Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Info

Publication number
MX2015009429A
MX2015009429A MX2015009429A MX2015009429A MX2015009429A MX 2015009429 A MX2015009429 A MX 2015009429A MX 2015009429 A MX2015009429 A MX 2015009429A MX 2015009429 A MX2015009429 A MX 2015009429A MX 2015009429 A MX2015009429 A MX 2015009429A
Authority
MX
Mexico
Prior art keywords
olopatadine
mometasone
combination
allergic rhinitis
treatment
Prior art date
Application number
MX2015009429A
Other languages
English (en)
Inventor
Abhay Kulkarni
Dinesh Pradeep Wale
Vikram Mansingh Bhosale
Piyush Agarwal
Patrick Keohane
Sudeesh K Tantry
Chad Oh
Neelima Khairatkar Joshi
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2015009429A publication Critical patent/MX2015009429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud de patente se refiere a un método para tratar la rinitis alérgica en un sujeto (preferentemente un ser humano) mediante la administración de una combinación de mometasona o su sal y olopatadina o su sal.
MX2015009429A 2013-10-04 2014-10-03 Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina. MX2015009429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Publications (1)

Publication Number Publication Date
MX2015009429A true MX2015009429A (es) 2015-10-09

Family

ID=51982657

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009429A MX2015009429A (es) 2013-10-04 2014-10-03 Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
MX2020003035A MX2020003035A (es) 2013-10-04 2015-07-22 Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003035A MX2020003035A (es) 2013-10-04 2015-07-22 Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Country Status (12)

Country Link
US (1) US10646500B2 (es)
EP (2) EP2922553A1 (es)
JP (3) JP6419195B2 (es)
CN (2) CN105792828A (es)
HK (1) HK1215674A1 (es)
MX (2) MX2015009429A (es)
MY (1) MY176808A (es)
PH (1) PH12015502302A1 (es)
RU (1) RU2686670C2 (es)
UA (1) UA120587C2 (es)
WO (1) WO2015049665A1 (es)
ZA (1) ZA201504740B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
AU2018260934B2 (en) * 2017-06-28 2023-10-19 Glenmark Specialty S.A. Dispensing device and pharmaceutical compositions for the treatment of rhinitis
BR112020016817A2 (pt) * 2018-02-23 2020-12-15 Glenmark Specialty S.A. Método para tratar sintomas associados à rinite alérgica, método para fornecer um início de ação mais rápido para alívio da rinite alérgica e método para tratar um sujeito humano pediátrico que sofre de rinite alérgica
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
AU7859800A (en) 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
PL376970A1 (pl) * 2002-11-12 2006-01-23 Alcon, Inc. Zastosowanie środka przeciwalergicznego i steroidu do leczenia alergicznego nieżytu nosa
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2586553C (en) 2004-11-24 2015-02-10 Alcon, Inc. Nasal sprayer containing a formulation with olopatadine
SI1919450T1 (sl) * 2005-09-01 2014-10-30 Meda Ab Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
WO2007064912A2 (en) 2005-12-02 2007-06-07 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
WO2007123193A1 (ja) 2006-04-21 2007-11-01 Toko Yakuhin Kogyo Kabushiki Kaisha スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
KR20110045004A (ko) * 2008-07-15 2011-05-03 쉐링 코포레이션 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
CN102470099A (zh) 2009-07-17 2012-05-23 爱尔康研究有限公司 儿童用奥洛他定鼻腔喷雾方案
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
EP2736491B1 (en) 2011-01-04 2017-04-05 Bausch & Lomb Incorporated Bepotastine compositions
BR112015009087A2 (pt) 2012-10-25 2017-11-14 Novozymes As método para lavagem de louça manual, e, composição detergente
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
PH12016500433B1 (en) 2013-09-13 2023-03-01 Glenmark Pharmaceuticals Ltd Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Also Published As

Publication number Publication date
RU2686670C2 (ru) 2019-04-30
EP4272839A2 (en) 2023-11-08
JP2018123157A (ja) 2018-08-09
US20150099725A1 (en) 2015-04-09
PH12015502302B1 (en) 2016-02-15
JP2020097624A (ja) 2020-06-25
WO2015049665A1 (en) 2015-04-09
EP4272839A3 (en) 2024-01-03
RU2015128496A (ru) 2017-11-13
PH12015502302A1 (en) 2016-02-15
RU2019104453A (ru) 2019-03-28
CN105792828A (zh) 2016-07-20
US10646500B2 (en) 2020-05-12
HK1215674A1 (zh) 2016-09-09
RU2015128496A3 (es) 2018-06-19
MX2020003035A (es) 2020-07-22
EP2922553A1 (en) 2015-09-30
JP2016531949A (ja) 2016-10-13
ZA201504740B (en) 2016-10-26
JP6419195B2 (ja) 2018-11-07
MY176808A (en) 2020-08-21
UA120587C2 (uk) 2020-01-10
CN112773808A (zh) 2021-05-11
JP6768733B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
HRP20181169T1 (hr) Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti
GB201320723D0 (en) Composition and methods of treatment
EP3013407A4 (en) Medical treatment system and method of use
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
IL240169A0 (en) Pyrimidine compositions for use in the treatment of diseases affected by ikke or tbk1 mechanisms
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
EP3084000A4 (en) Method of diagnosis and treatment
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
EP2948195A4 (en) INCLUDED DEVICES FOR THE TREATMENT OF MEDICAL WASTE AND METHOD FOR THE USE THEREOF
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EP3066077A4 (en) Treatment of cardiac remodeling and other heart conditions
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
GB201609383D0 (en) Improvements in or relating to methods of patient monitoring
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLENMARK SPECIALTY S.A.

FG Grant or registration